#EAU24 eURO Auditorium2 plenary session on #KidneyCancer

Hot debate on: Intensified treatment paradigms in first-line metastatic kidney cancer: Triplet combinations at any cost - is more always better?

Pros
✅ improve PFS
✅ Control of aggressive disease
✅ possibly…

Fantastic #RESECT results (200 centres, n=16000). Cluster RCT in NMIBC - performance feedback & education ⬆️ documentation of tumour pattern & resection completeness but not MMC admin or detrusor muscle. 🚨Taking part in audit DID ⬇️ recurrence rates by 25%🚨 #EAU24 @uroweb

✍️Read the report on the #ProstateCancer Game changing session at #EAU24 : New F/U data showing therapeutic benefit of extended PLND; and the latest real-world evidence from the Europa Uomo Prostate Partners’ Experience Research. #QoL
Learn more here 👉 eaucongress.uroweb.org/pca-game-chang…

New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47) #EAU24

Our UROONCO editorial boards were busy interviewing renowned speakers at #EAU24 on hot topics in GU cancers which are being presented at EAU24. Stay tuned!

#prostatecancer #bladdercancer #kidneycancer

Benjamin Pradere Giancarlo Marra Pawel Rajwa

Behind the scenes of today’s video interview with Prof. Alex Mottrie.

We talked about the #evolution of #techniques & #technologies in the field of #robotic #surgery for #kidney #cancer .

Stay tuned! This will be online 🔜 on the European Association of Urology (EAU) EAU Edu Platform UROONCO platform!

Great plenary session about personalising treatment for high-risk and metastasic prostate cancer at #EAU24 day 3
European Association of Urology (EAU)

🚨 #EAU24 Small renal masses session:

Dr. Amparore (Daniele Amparore) taking the stage presenting multi-institutional findings of tumor type after surgery for small renal masses in young cohort patients.

📣 #EAU24 Sunday session coming 🔥with EAU-YAU RCC working group members presentations on:

☑️ implications of newly -proposed TNM classification for RCC
☑️Quality metrics for #renalcellcarcinoma surgical care and much more!

Riccardo Campi Zhenjie Wu, MD, PhD European Association of Urology (EAU)

Some challenges to the #EAUGuidelines ? ✍️ The latest results on the PRIME study, PROBASE trial & ProScreen featured during the #ProstateCancer Game changing session at #EAU24 today.

Read the report here to learn more about the results 👇
eaucongress.uroweb.org/game-changers-…

Very interesting session about integrating a #robotic program with the advent of SP platform in Europe.
Top key opinion leaders Simone Crivellaro, Ketan K. Badani MD and Dr. J. Kaouk provided the audience their insights after 5 years of experience!
Great talks!

Final surgery of today for AZ Maria Middelares team during #EAU24 live surgery: 🤖partial nephrectomy guided by 3D model with perfusion info
🙏great collab effort UGent Geneeskunde & Gezondheidswetenschappen Faculty of Engineering and Architecture UGent Orsi Innotech Pieter De Backer Sarah Buelens Brecht Jacobs
European Association of Urology (EAU) Nina Harke Derya Tilki, MD Alberto Breda

Really interesting new data on PCa screening #EAU24 Re-Imagine trial Caroline Moore shows many PCa in men < 3 ng/mL but Göteborg-2 trial shows possible overdiagnosis in 1.8-3 ng/mL European Urology. PRAISE-U and Organized Prostate Testing programs will provide more data. Praise_U

🚨 Breaking results 🚨 PRIME Trial UCL study presented at #EAU24 European Association of Urology (EAU). This 🌍 multicentre trial (n=555, 22 sites) showed that biparametric MRI without contrast is non-inferior 2 multiparametric MRI & should be the new standard for prostate cancer diagnosis if image quality is good

Today at #EAU24 we saw a Plenary Session dedicated to risk-adapted screening of #PCa . The session took a wide look at the latest developments, covering PRAISE-U, new 15-year outcomes of the CAP trial and lectures that offered patient, genetic and international perspectives.

#EAU24 Comparison of Amer. Urol. Assn. & European Association of Urology (EAU) risk strat models of UTUC
UroToday.com

2-yr RFS rate, LR v HR
📌AUA 58% v 45% (p=0.007) c-ind 0.56
📌EAU 79% v 32% (p<0.001) c-ind 0.72

2-yr prog rate, LR v HR
📌AUA 79% v 71% (p=0.10) c-ind 0.55
📌EAU 86% v 65% (p<0.001) c-ind 0.66

#EAU24 ✍️ Read today's report from the Plenary: Controversies in #GUCancer staging: Is it only imaging? Highlights: Molecular imaging, biomarkers, PSMA M1a positive patient, PSMA PET standardisation, & the ‘Oncidium Initiative’ #Radiotheranostics

👉eaucongress.uroweb.org/plenary-sessio…

Serial ctDNA testing, a better risk-stratification tool? Does adjuvant NIVO have more benefits than PBO in ITT & PD-L1 ≥ 1 populations?
More IMvigor011 & CheckMate 274 updates at #EAU24 Game-Changing Session lectures by Tom Powles & Matt Galsky

👉 eaucongress.uroweb.org/game-changing-…

With Matt Galsky #EAU24 adjuvant nivolumab in bladder ca: HR 0.76 in ITT & 0.56 in PD-L1 +ve. Clinically meaningful results especially in PD-L1 +ves. No data on PD-L1-ve! OS is not yet significant but this data is impressive. ~60% relapse and 24% get subsequent IO. ~10% ⬆️tox.

Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24 . Do we need to give adjuvant therapy to those as such low risk?